Fritsch, K. and Kasenda, B. and Schorb, E. and Hau, P. and Bloehdorn, J. and Moehle, R. and Loew, S. and Binder, M. and Atta, J. and Keller, U. and Wolf, H-H and Krause, S. W. and Hess, G. and Naumann, R. and Sasse, S. and Hirt, C. and Lamprecht, M. and Martens, U. and Morgner, A. and Panse, J. and Frickhofen, N. and Roeth, A. and Hader, C. and Deckert, M. and Fricker, H. and Ihorst, G. and Finke, J. and Illerhaus, G. (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). LEUKEMIA, 31 (4). pp. 846-852. ISSN 0887-6924, 1476-5551
Full text not available from this repository. (Request a copy)Abstract
To investigate immuno-chemotherapy for elderly immuno-competent patients (. 65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m(2), days 1, 15, 29), high-dose methotrexate (3 g/m(2) days 2, 16, 30), procarbazine (60 mg/m(2) days 2-11) and lomustine (110 mg/m(2), day 2)-R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less. grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NERVOUS-SYSTEM LYMPHOMA; PHASE-II; EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; PROCARBAZINE; RITUXIMAB; RADIOTHERAPY; TEMOZOLOMIDE; POPULATION; CYTARABINE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:00 |
| Last Modified: | 25 Feb 2019 10:49 |
| URI: | https://pred.uni-regensburg.de/id/eprint/176 |
Actions (login required)
 |
View Item |
